Recall
FDAHealthDecember 18, 2025

Imprimis NJOF, LLC — Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 713

⚠️ Presence of particulate matter - Glass like particles.

Is this relevant to me?

Geography
Nationwide
Source agency
FDA
Category
Health
Published
December 18, 2025

U.S Nationwide

What's affected?

Product
Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.
Lot code
25JAN033A

Additional details

Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.

What should I do?

Recommended action

Class II recall. Voluntary: Firm initiated Quantity affected: 314 boxes of 6,280 pre-filled syringes.

View original FDA notice →

Get Health recall alerts

Delivered to your inbox. Free. No account required.